ClinicalTrials.gg
Not yet recruitingNCT07941804Updated Nov 17, 2026

Telehealth Stepped Care for Child and Adolescent Mental Health

An interventional study of 12-Session Telehealth Cognitive Behavioral Therapy and 4-Session Telehealth Cognitive Behavioral Therapy in Anxiety, Depression Symptom and Disruptive Behaviors, sponsored by Child Mind Institute. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Child Mind Institute · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Depression with a site in Brazil — 18 open to participants now, 23 under way, 3 of them phase 3. Depression · Brazil.

Planned enrollment
2nd of 90
4,000 · median 80
Started
2026
with 7 others
No phase
61 of 99
12 open now
Primary completion
2027-11
later than 18 of 22 live
Registered
98th of 99
by date

Among the 99 studies in Depression with a site in Brazil, this one is the 2nd largest by planned enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2026, is one of 61 with no phase, reaches primary completion later than 18 of the 22 other live ones, and was the 98th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

18 of the 99 studies in Depression with a site in Brazil are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 6 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Depression with a site in Brazil, or all of them as a file.
02

Study summary

This study will evaluate a telehealth-delivered stepped-care model to improve access to mental health support for children and adolescents in Brazil and South Africa. The study will include children and adolescents aged 6 to 18 years who have concerns related to anxiety, depression, irritability, or disruptive behavior.

Participants will first complete an online mental health assessment. Depending on their symptom level, they may receive psychoeducational materials, a brief single-session intervention, or additional mental health support. Participants whose symptoms remain elevated after the single-session intervention may be randomly assigned to one of three groups: four-session cognitive behavioral therapy, twelve-session cognitive behavioral therapy, or more intensive psychoeducational materials.

The study will compare changes in mental health symptoms across the three groups. It will also evaluate whether the interventions are acceptable, feasible, safe, and suitable for delivery through telehealth. Participants will complete assessments at baseline, during treatment, after treatment, and approximately six months later.

Read the detailed description

This is a multicountry, randomized, open-label, three-arm clinical trial evaluating a stepped-care telehealth model for child and adolescent mental health in Brazil and South Africa.

The study will recruit children and adolescents aged 6 to 18 years and their caregivers. Depending on age and symptom domain, assessments and interventions may be completed by the child or adolescent, the primary caregiver, or both. The study will address symptoms of anxiety, depression, and disruptive or oppositional behavior.

The study includes sequential phases. In the initial phase, participants will complete an online assessment using the LUMI Global measure and related measures. Participants with low or subclinical symptom levels will receive psychoeducational materials. Participants with subclinical symptoms may be reassessed after approximately four weeks. Participants with elevated symptoms will be invited to receive a brief, single-session intervention delivered remotely by trained personnel.

Approximately one week after the single-session intervention, participants will complete a follow-up assessment. Participants whose symptoms remain at a clinically elevated level and who meet the criteria for the next stage of care will be randomized in a 1:1:1 ratio to one of three groups:

  1. - Four-session cognitive behavioral therapy delivered by telehealth;
  2. - Twelve-session cognitive behavioral therapy delivered by telehealth; or
  3. - Enhanced psychoeducational materials without therapist-delivered cognitive behavioral therapy.

The cognitive behavioral therapy protocols will be directed toward the participant's predominant symptom domain, which may include anxiety, depression, or disruptive behavior. The interventions will be adapted for the relevant age group and country while maintaining the core components of the study protocols.

The primary outcome will be treatment response at 12 weeks after randomization, defined as a reduction of at least 50% in symptoms measured with domain-specific instruments. Secondary outcomes will include symptom change at four weeks and six months, functioning, participant and caregiver satisfaction, acceptability, engagement, treatment completion, intervention fidelity, safety, and adverse effects.

All interventions will be delivered remotely through telehealth.

03

Conditions studied

  • Anxiety
  • Depression Symptom
  • Disruptive Behaviors
  • Child and Adolescent Mental Health

Browse trials for

Keywords

  • Telehealth
  • Stepped Care
  • Cognitive Behavioral Therapy
  • Single-Session Intervention
  • Psychoeducation
  • Child and Adolescent Mental Health
  • Digital Mental Health
  • Randomized Controlled Trial
  • Brazil
  • South Africa
  • Depression
  • Anxiety
  • Disruptive Behaviors
04

In context

Depression Reclassified

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 81 across 7,078 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Child Mind Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be children or adolescents aged 6 to 18 years living in Brazil or in the participating regions of South Africa, including the Western Cape or KwaZulu-Natal;
  • Have concerns related to emotional or behavioral symptoms, including anxiety, depressed mood, irritability, oppositionality, aggression, or other significant behavioral difficulties;
  • Be able to communicate in a language supported by the study team and intervention materials;
  • Have from a parent or legal guardian when required and provide assent when applicable. Participants who are legally adults will provide their own informed consent.

Eligibility for each study pathway will be determined sequentially:

  • Participants will first complete the LUMI Global assessment.
  • Participants with low or subclinical symptoms will receive psychoeducational materials. Participants with subclinical symptoms may be reassessed after approximately four weeks.
  • Participants with symptom scores at or above 1.5 standard deviations above the reference mean may be invited to receive the remote single-session intervention.
  • Participants may enter the randomized intervention phase if they complete the single-session intervention and continue to have symptom scores at or above 1.5 standard deviations above the reference mean at follow-up.

Exclusion criteria

Exclusion Criteria:

  • High suicidal risk identified during study screening or clinical assessment, requiring referral to more intensive care;
  • Elevated conduct disorder symptoms on the LUMI Global conduct disorder subscales, above the protocol-defined threshold;
  • Signs of autism spectrum disorder or intellectual disability, as assessed by the study clinician, to a degree likely to prevent the participant from benefiting from the intervention (a reported diagnosis alone is not grounds for exclusion);
  • Not completing the single-session intervention within the protocol-defined time window, unless eligibility is re-established;
  • Lack of the language ability, digital access, or connectivity needed to participate in study procedures; or
  • Not providing required consent or assent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
4,000 participants (estimated)

Study arms

  • Experimental
    12-Session Telehealth Cognitive Behavioral Therapy

    Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive a structured 12-session cognitive behavioral therapy intervention delivered remotely by trained providers. The intervention will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for the participant's age and presentation. Sessions may involve the participant, the primary caregiver, or both. Participants will complete follow-up assessments at approximately 4 weeks, 12 weeks, and 6 months after randomization.

    Behavioral: 12-Session Telehealth Cognitive Behavioral Therapy

  • Experimental
    4-Session Telehealth Cognitive Behavioral Therapy

    Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive a structured 4-session cognitive behavioral therapy intervention delivered remotely by trained providers. The intervention will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for the participant's age and presentation. Sessions may involve the participant, the primary caregiver, or both. Participants will complete follow-up assessments at approximately 4 weeks, 12 weeks, and 6 months after randomization.

    Behavioral: 4-Session Telehealth Cognitive Behavioral Therapy

  • Active comparator
    Enhanced Psychoeducational Materials

    Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive enhanced psychoeducational materials without therapist-delivered cognitive behavioral therapy. Materials will include videos and short texts addressing mental health symptoms and coping strategies. Participants will complete follow-up assessments at approximately 4 weeks, 12 weeks, and 6 months after randomization. Participants may continue to receive usual care and referrals throughout the study.

    Behavioral: Enhanced Psychoeducational Materials

Interventions

  • Behavioral12-Session Telehealth Cognitive Behavioral Therapy

    Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive 12 structured cognitive behavioral therapy sessions delivered remotely by trained providers. The protocol will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for age and clinical presentation. Sessions may involve the participant, the primary caregiver, or both.

  • Behavioral4-Session Telehealth Cognitive Behavioral Therapy

    Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive 4 structured cognitive behavioral therapy sessions delivered remotely by trained providers. The protocol will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for age and clinical presentation. Sessions may involve the participant, the primary caregiver, or both.

  • BehavioralEnhanced Psychoeducational Materials

    Participants randomized to the active comparator group will receive more intensive psychoeducational materials without therapist-delivered cognitive behavioral therapy. The materials will include videos and short texts addressing mental health symptoms, emotional well-being, and coping strategies. Participants may continue usual care and referrals throughout the study.

07

What researchers measure

Primary outcomes

  1. Treatment Response at 12 Weeks After Randomization

    Proportion of participants with a reduction of at least 50% in the symptom score for the predominant clinical domain from the start of the randomized intervention phase to 12 weeks after randomization. Anxiety symptoms will be measured using the RCADS-25 Anxiety subscale, depressive symptoms using the RCADS-25 Depression subscale, and disruptive behavior using the SNAP-IV Oppositionality items. For participants aged 6-11 years, caregiver report will be used. For participants aged 12-18 years, caregiver and adolescent self-report will be collected, and participants will be classified as responders if either informant demonstrates at least a 50% reduction.

    Time frame: 12 weeks after randomization

Secondary outcomes

  1. Percentage of Participants for Whom the Single-Session Intervention Is Sufficient

    Percentage of participants who received the single-session intervention (SSI) whose overall 20-item LUMI (Library of Universal Mental Health Instruments) Screener score falls below 1.5 SD above the reference mean, and who therefore do not require stepped-up care. The percentage scoring below 0.75 SD above the reference mean will also be reported.

    Time frame: 1 to 2 weeks after the single-session intervention

  2. Symptom Response at 4 Weeks and 6 Months

    Proportion with ≥50% symptom reduction from randomization.

    Time frame: 4 weeks and 6 months after randomization

  3. Remission at 12 Weeks

    Proportion with a domain-specific T-score below 55.

    Time frame: 12 weeks after randomization

  4. Number of Participants With Reliable Improvement, No Reliable Change, or Reliable Deterioration

    Clinical change classified with the Reliable Change Index (Jacobson \& Truax, 1991) on the participant's primary outcome measure: Revised Child Anxiety and Depression Scale, 25-item version (RCADS-25) Anxiety subscale (range 0 to 45), RCADS-25 Depression subscale (range 0 to 30), or Swanson, Nolan, and Pelham Questionnaire, Version IV (SNAP-IV) Oppositionality items (range 0 to 24). Higher scores indicate worse symptoms. Change is calculated from the randomization assessment.

    Time frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

  5. Change in RCADS-25 Anxiety Subscale Score

    Change in the Revised Child Anxiety and Depression Scale, 25-item version (RCADS-25) Anxiety subscale score among participants whose primary domain is anxiety. The subscale has 15 items rated 0 (never) to 3 (always); total range 0 to 45. Higher scores indicate worse anxiety symptoms.

    Time frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

  6. Change in LUMI Functioning Score

    Change in the Library of Universal Mental Health Instruments (LUMI) Functionality score. The 7 items assess how difficult it was in the past 30 days to communicate, move around, take care of oneself, do activities at home, do school or work activities, do fun or meaningful activities, and get along with people. Each item is rated from 1 (very easy) to 5 (very difficult or cannot do it); the score is the mean of answered items, range 1 to 5. Higher scores indicate worse functioning. Caregiver report for ages 6 to 11; caregiver report and self-report for ages 12 to 18.

    Time frame: Baseline, 1 to 2 weeks after the single-session intervention, and 4 weeks, 12 weeks, and 6 months after randomization

  7. Non-Inferiority of 4-Session CBT

    Comparison of 4-session versus 12-session CBT using a 25-percentage-point non-inferiority margin.

    Time frame: 12 weeks after randomization

  8. Percentage of Participants With at Least 50% Symptom Reduction, by Intervention Protocol

    Percentage of participants with at least a 50% reduction in the primary outcome score from randomization, reported separately for each intervention protocol: child anxiety and adolescent anxiety (RCADS-25 Anxiety subscale), adolescent depression (RCADS-25 Depression subscale), and child disruptive behavior (SNAP-IV Oppositionality items). This is an exploratory analysis; the trial is not powered to detect differences between protocols.

    Time frame: 12 weeks after randomization

  9. Mean Score on the Study Satisfaction Questionnaire

    Participant and caregiver satisfaction measured with a questionnaire developed for this study (positive experience items, e.g., feeling welcomed, listened to, and helped by the therapist). Each item is rated from 1 (not at all) to 5 (extremely); the score is the mean of answered items, range 1 to 5. Higher scores indicate greater satisfaction.

    Time frame: 1 to 2 weeks after the single-session intervention and 12 weeks after randomization

  10. Change in Top Problems Assessment (TPA) Mean Severity Score

    The participant and caregiver each identify up to three problems most important to them and rate the severity of each from 0 to 4. The score is the mean severity across the identified problems, range 0 to 4. Higher scores indicate more severe problems.

    Time frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

  11. Percentage of Participants Referred to Higher-Intensity Care

    Percentage of participants referred to more intensive mental health care, based on REDCap tracking records and therapist reports.

    Time frame: From enrollment up to 6 months after randomization

  12. Percentage of Participants Reporting at Least One Therapy-Specific Adverse Effect

    Measured with the Therapy-Specific Adverse Effects Scale: 8 statements (e.g., "My mental health is worse because of therapy"), each rated on a 5-point scale (completely agree, agree, neither agree nor disagree, disagree, completely disagree). An item is considered endorsed when rated "agree" or "completely agree". The number of endorsed items (range 0 to 8) will also be reported; higher numbers indicate more adverse effects.

    Time frame: 12 weeks and 6 months after randomization

  13. Change in RCADS-25 Depression Subscale Score

    Change in the Revised Child Anxiety and Depression Scale, 25-item version (RCADS-25) Depression subscale score among participants whose primary domain is depression. The subscale has 10 items rated 0 (never) to 3 (always); total range 0 to 30. Higher scores indicate worse depressive symptoms.

    Time frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

  14. Change in SNAP-IV Oppositionality Subscale Score

    Change in the Swanson, Nolan, and Pelham Questionnaire, Version IV (SNAP-IV) Oppositionality subscale score among participants whose primary domain is disruptive behavior. The subscale has 8 items rated 0 (not at all) to 3 (very much); total range 0 to 24. Higher scores indicate worse oppositional behavior.

    Time frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

  15. Net Promoter Score

    Likelihood of recommending this type of care, measured with a single Net Promoter Score item: "Based on your experience with this/these session(s), on a scale from 1 to 10 where 1 is not at all and 10 is extremely, what is the likelihood of you recommending this type of care to others with similar difficulties?" Rated from 1 (not at all) to 10 (extremely). Higher scores indicate greater satisfaction.

    Time frame: 1 to 2 weeks after the single-session intervention and 12 weeks after randomization

  16. Percentage of Participants With Emergent Suicidal Ideation

    Percentage of participants who answer "more than half the days" or "nearly every day" to item 9 of the Patient Health Questionnaire-9 (PHQ-9): "Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?"

    Time frame: 1 to 2 weeks after the single-session intervention, and 4 weeks, 12 weeks, and 6 months after randomization

Other outcomes

  1. Percentage of Scheduled Intervention Sessions Attended and Completed

    Percentage of scheduled single-session intervention and CBT sessions that were attended and completed, based on REDCap tracking records.

    Time frame: From intervention initiation through completion of the assigned intervention, up to 12 weeks after randomization

  2. Percentage of Randomized Participants Completing the 6-Month Follow-Up Assessment

    Percentage of randomized participants who complete the 6-month follow-up assessment (retention), based on REDCap tracking records.

    Time frame: From enrollment through the 6-month follow-up

  3. Percentage of Sessions Delivered by Videoconference Rather Than Phone Call

    Percentage of single-session intervention and CBT sessions conducted by videoconference rather than phone call, based on Thinkific platform metadata, REDCap records, and counsellor session logs.

    Time frame: During the single-session intervention and the randomized intervention period, up to 12 weeks after randomization

  4. Percentage of Planned Session Content Covered, Rated From Session Recordings

    Therapist fidelity, measured as the percentage of planned core session content covered, rated by structured review of session recordings using the protocol adherence checklist.

    Time frame: Each single-session intervention and CBT session, up to 12 weeks after randomization

  5. Percentage of Participants Rating the Intervention as Helpful

    Percentage of participants and caregivers who answer "helped a lot" or "helped a little bit" to the perceived impact item of the study Satisfaction Questionnaire ("Overall, how did the session(s) with the therapist affect the difficulties you/your child was experiencing?").

    Time frame: Immediately after the single-session intervention and 12 weeks after randomization

  6. Percentage of Sessions Left Incomplete Due to Platform, Device, or Connectivity Problems

    Percentage of single-session intervention and CBT sessions that could not be completed because of platform, device, or internet connectivity problems, based on Thinkific platform metadata, REDCap records, and counsellor session logs.

    Time frame: During the single-session intervention and the randomized intervention period, up to 12 weeks after randomization

  7. Percentage of Adherence Checklist Items Completed, Therapist Self-Report

    Therapist adherence, measured as the percentage of protocol adherence checklist items the therapist reports as completed after each session.

    Time frame: Each single-session intervention and CBT session, up to 12 weeks after randomization

  8. Percentage of Participants Rating the Intervention as Culturally Appropriate

    Percentage of participants and caregivers who rate the study Satisfaction Questionnaire item "The language and examples used in therapy felt appropriate for my (our) context" as "a lot" or "extremely" (5-point scale from "not at all" to "extremely").

    Time frame: Immediately after the single-session intervention and 12 weeks after randomization

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the study results may be shared. Direct identifiers, contact information, audio or video recordings, and information that could reasonably identify participants will not be shared. Data from Brazil and South Africa may be combined for collaborative analyses.

Supporting information: Study protocol

Time frame: De-identified IPD and supporting information will become available after publication of the primary study results and completion of applicable ethics, governance, and data-transfer requirements. There is no planned end date for availability, subject to continued availability of the secure repository and applicable regulations.

Access criteria: Access may be granted to qualified researchers who submit a scientifically justified research proposal and agree to applicable ethics requirements, institutional approvals, data-use restrictions, and confidentiality obligations. Access will be limited to de-identified IPD and the approved supporting information through a secure, controlled-access repository or data-transfer process.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 3,479 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 3,577 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Nov 17, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07941804
Lead sponsor
Child Mind Institute
Collaborators
Medical Research Council, South Africa, Hospital de Clinicas de Porto Alegre, TelessaúdeRS / UFRGS, Stavros Niarchos Foundation
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Luciane Piccolo, PhD
Contact
luciane.piccolo@childmind.org
646-407-6476
Giovanni Abrahão Salum, MD, PhD
Contact
giovanni.salum@childmind.org
917-631-5527
Carrie Brooke-Sumner, PhD
principal investigator · Medical Research Council, South Africa
Luis Augusto Rohde, MD, PhD
principal investigator · Hospital de Clinicas de Porto Alegre
Giovanni Abrahão Salum, MD, PhD
study director · Hospital de Clinicas de Porto Alegre
Zeina Mneimneh, PhD, MS, MPH
study director · Child Mind Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion